Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.62 - $5.5 $54,978 - $65,450
-11,900 Reduced 24.14%
37,400 $196,000
Q1 2024

May 15, 2024

BUY
$3.94 - $6.65 $107,562 - $181,545
27,300 Added 124.09%
49,300 $268,000
Q4 2023

Feb 14, 2024

BUY
$3.46 - $5.73 $76,120 - $126,060
22,000 New
22,000 $113,000
Q2 2023

Aug 14, 2023

BUY
$2.6 - $5.19 $13,780 - $27,507
5,300 New
5,300 $16,000
Q4 2022

Feb 14, 2023

SELL
$4.54 - $6.6 $194,766 - $283,140
-42,900 Reduced 86.49%
6,700 $34,000
Q3 2022

Nov 14, 2022

BUY
$0.1 - $7.82 $2,700 - $211,140
27,000 Added 119.47%
49,600 $311,000

Others Institutions Holding NVNO

About enVVeno Medical Corp


  • Ticker NVNO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 9,469,850
  • Market Cap $34.5M
  • Description
  • enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency...
More about NVNO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.